.png)
Biotech Bulls & Breakthroughs
Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.
Biotech Bulls & Breakthroughs
Ep. 2: The Future of Oncology: Key Takeaways from ASCO | Biotech Bulls & Breakthroughs Podcast
In this episode, John Gagliano and Sheff discuss the recent ASCO conference, its significance in the oncology space, and key takeaways from the event. They delve into the importance of biotech conferences for investors, analyze oncology companies and their drug development strategies, and explore investment strategies focusing on smaller biotech firms. The conversation also touches on the role of AI in drug development and highlights current watchlist stocks with upcoming catalysts.
In this episode:
🔹 ASCO Recap & Conferences
🔹 AI in drug development
🔹 M&A Biotech Activity
Sheff is proud to support the Northwest Association for Blind Athletes. Join us in empowering life-changing opportunities for visually impaired youth and adults through sports and community engagement. You can support this as well in the link below:
Support NWABA: https://nwaba.org/support/other-ways-to-help/sheffstation/#join-sheff-station
🧠Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades
📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
📲 Follow Sheff: https://x.com/SheffStation
Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.
